|
1
|
McKillop IH, Moran DM, Jin X and Koniaris
LG: Molecular pathogenesis of hepatocellular carcinoma. J Surg Res.
136:125–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J, Boix L, Sala M and Llovet JM:
Focus on hepatocellular carcinoma. Cancer Cell. 5:215–219. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trevisani F, Cantarini MC, Wands JR and
Bernardi M: Recent advances in the natural history of
hepatocellular carcinoma. Carcinogenesis. 29:1299–1305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kusakabe A, Tanaka Y, Orito E, et al: A
weak association between occult HBV infection and non-B non-c
hepatocellular carcinoma in Japan. J Gastroenterol. 42:298–305.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB, Siegel AB, Davila JA, Shaib
YH, Cayton-Woody M, McBride R and McGlynn KA: Treatment and
outcomes of treating of hepatocellular carcinoma among Medicare
recipients in the United States: a population-based study. J
Hepatol. 44:158–166. 2006. View Article : Google Scholar
|
|
6
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plataniotis G and Castiglione M; ESMO
Guidelines Working Group. Endometrial cancer : ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 2:v41–v45. 2010. View Article : Google Scholar
|
|
8
|
Gehrig PA and Bae-Jump VL: Promising novel
therapies for the treatment of endometrial cancer. Gynecol Oncol.
116:187–194. 2010. View Article : Google Scholar
|
|
9
|
Middleton E Jr, Kandaswami C and
Theoharides TC: The effects of plant flavonoids on mammalian cells:
implications for inflammation, heart disease, and cancer. Pharmacol
Rev. 52:673–751. 2000.PubMed/NCBI
|
|
10
|
Li YL, Gan GP, Zhang HZ, Wu HZ, Li CL,
Huang YP, Liu YW and Liu JW: A flavonoid glycoside isolated from
Smilax china L. rhizome in vitro anticancer effects on human cancer
cell lines. J Ethnopharmacol. 113:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Díaz JG, Carmona AJ, Torres F, Quintana J,
Estévez F and Herz W: Cytotoxic activities of flavonoid glycoside
acetates from Consolida oliveriana. Planta Med. 74:171–174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Wang H, Wu J, Zhu D, Zhang X, Ou
L, Yu Y and Lou Y: Enhanced co-expression of beta-tubulin III and
choline acetyltransferase in neurons from mouse embryonic stem
cells promoted by icaritin in an estrogen receptor-independent
manner. Chem Biol Interact. 179:375–385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wo YB, Zhu DY, Hu Y, Wang ZQ, Liu J and
Lou YJ: Reactive oxygen species involved in prenylflavonoids,
icariin and icaritin, initiating cardiac differentiation of mouse
embryonic stem cells. J Cell Biochem. 103:1536–1550. 2008.
View Article : Google Scholar
|
|
14
|
Zhang G, Qin L, Sheng H, Wang XL, Wang YX,
Yeung DK, Griffith JF, Yao XS, Xie XH, Li ZR, Lee KM and Leung KS:
A novel semisynthesized small molecule icaritin reduces incidence
of steroid-associated osteonecrosis with inhibition of both
thrombosis and lipid-deposition in a dose-dependent manner. Bone.
44:345–356. 2009. View Article : Google Scholar
|
|
15
|
Huang X, Zhu D and Lou Y: A novel
anticancer agent, icaritin, induced cell growth inhibition, Gl
arrest and mitochondrial transmenbrane potential drop in human
prostate carcinoma PC-3 cells. Eur J Pharmacol. 564:26–36. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang ZQ and Lou YJ:
Proliferation-stimulating effects of icaritin and desmethylicaritin
in MCF-7 cells. Eur J Pharmacol. 504:147–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo Y, Zhang X, Meng J and Wang ZY: An
anticancer agent icaritin induces sustained activation of the
extracellular signal-regulated kinase (ERK) pathway and inhibits
growth of breast cancer cells. Eur J Pharmacol. 658:114–122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tong JS, Zhang QH, Huang X, Fu XQ, Qi ST,
Wang YP, Hou Y, Sheng J and Sun QY: Icaritin causes sustained
ERK1/2 activation and induces apoptosis in human endometrial cancer
cells. PLoS One. 6:e167812011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou NN, Tang J, Chen WD, Feng GK, Xie BF,
Liu ZC, Yang D and Zhu XF: Houttuyninum, an active constituent of
Chinese herbal medicine, inhibits phosphorylation of HER2/neu
receptor tyrosine kinase and the tumor growth of
HER2/neu-overexpressing cancer cells. Life Sci. 90:770–775. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang CZ, Calway T and Yuan CS: Herbal
medicines as adjuvants for cancer therapeutics. Am J Chin Med.
40:657–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ben-Arye E, Schiff E, Hassan E, Mutafoglu
K, Lev-Ari S, Steiner M, Lavie O, Polliack A, Silbermann M and Lev
E: Integrative oncology in the Middle East: from traditional herbal
knowledge to contemporary cancer care. Ann Oncol. 23:211–221. 2012.
View Article : Google Scholar
|
|
23
|
Li J, Liu P, Zhang R, Cao L, Qian H, Liao
J, Xu W, Wu M and Yin Z: Icaritin induces cell death in activated
hepatic stellate cells through mitochondrial activated apoptosis
and ameliorates the development of liver fibrosis in rats. J
Ethnopharmacol. 137:714–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Wu J, Chen X, Fortenbery N,
Eksioglu E, Kodumudi KN, Pk EB, Dong J, Djeu JY and Wei S: Icariin
and its derivative, ICT, exert anti-inflammatory, anti-tumor
effects, and modulate myeloid derived suppressive cells (MDSCs)
functions. Int Immunopharmacol. 11:890–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang J, Yuan L, Wang X, Zhang TL and Wang
K: Icaritin and its glycosides enhance osteoblastic, but suppress
osteoclastic, differentiation and activity in vitro. Life Sci.
81:832–840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He J, Wang Y, Duan F, Jiang H, Chen MF and
Tang SY: Icaritin induces apoptosis of HepG2 cells via the JNK1
signaling pathway independent of the estrogen receptor. Planta Med.
76:1834–1839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Golbano JM, Lóppez-Aparicio P, Recio MN
and Pérez-Albarsanz MA: Finasteride induces apoptosis via Bcl-2,
Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer
cell line. Int J Oncol. 32:919–924. 2008.PubMed/NCBI
|
|
28
|
Kroemer G and Reed JC: Mitochondrial
control of cell death. Nat Med. 6:513–519. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van Loo G, Saelens X, van Gurp M,
MacFarlane M, Martin SJ and Vandenabeele P: The role of
mitochondrial factors in apoptosis: a Russian roulette with more
than one bullet. Cell Death Differ. 9:1031–1042. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Llambi F, Moldoveanu T, Tait SW,
Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP and Green DR:
A unified model of mammalian BCL-2 protein family interactions at
the mitochondria. Mol Cell. 44:517–531. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X: The expanding role of mitochondria
in apoptosis. Genes Dev. 15:2922–2933. 2001.PubMed/NCBI
|
|
32
|
Susnow N, Zeng L, Margineantu D and
Hockenbery DM: Bcl-2 family proteins as regulators of oxidative
stress. Semin Cancer Biol. 19:42–49. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tait SW and Green DR: Mitochondria and
cell death: outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamaguchi Y, Shiraki K, Fuke H, Inoue T,
Miyashita K, Yamanaka Y and Nakano T: Adenovirus-mediated
transfection of caspase-8 sensitizes hepatocellular carcinoma to
TRAIL- and chemotherapeutic agent-induced cell death. Biochim
Biophys Acta. 1763:844–853. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang SH, Chen LM, Yang WK and Lee JD:
Increased extrinsic apoptotic pathway activity in patients with
hepatocellular carcinoma following transarterial embolization.
World J Gastroenterol. 17:4675–4681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Muppidi JR and Siegel RM:
Ligand-independent redistribution of Fas (CD95) into lipid rafts
mediates clonotypic T cell death. Nat Immunol. 5:182–189. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abd El-Ghany RM, Sharaf NM, Kassem LA,
Mahran LG and Heikal OA: Thymoquinone triggers anti-apoptotic
signaling targeting death ligand and apoptotic regulators in a
model of hepatic ischemia reperfusion injury. Drug Discov Ther.
3:296–306. 2009.PubMed/NCBI
|
|
39
|
Hyer ML, Shi R, Krajewska M, Meyer C,
Lebedeva IV, Fisher PB and Reed JC: Apoptotic activity and
mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and
related synthetic triterpenoids in prostate cancer. Cancer Res.
68:2927–2933. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Zhang Y, Zhang L, Yang X and Lv
Z: Lupeol, a dietary triterpene, inhibited growth, and induced
apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer
Invest. 27:163–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
